CN1496350A - 制备纯二水合昂丹司琼盐酸盐的改进方法 - Google Patents

制备纯二水合昂丹司琼盐酸盐的改进方法 Download PDF

Info

Publication number
CN1496350A
CN1496350A CNA028062019A CN02806201A CN1496350A CN 1496350 A CN1496350 A CN 1496350A CN A028062019 A CNA028062019 A CN A028062019A CN 02806201 A CN02806201 A CN 02806201A CN 1496350 A CN1496350 A CN 1496350A
Authority
CN
China
Prior art keywords
ondansetron
solution
hydrochloride dihydrate
precipitate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028062019A
Other languages
English (en)
Chinese (zh)
Inventor
Rl
R·L·哈达斯
E·巴查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1496350A publication Critical patent/CN1496350A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA028062019A 2001-01-11 2002-01-11 制备纯二水合昂丹司琼盐酸盐的改进方法 Pending CN1496350A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
US60/261,052 2001-01-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101667179A Division CN101045704A (zh) 2001-01-11 2002-01-11 制备纯二水合昂丹司琼盐酸盐的改进方法

Publications (1)

Publication Number Publication Date
CN1496350A true CN1496350A (zh) 2004-05-12

Family

ID=22991757

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028062019A Pending CN1496350A (zh) 2001-01-11 2002-01-11 制备纯二水合昂丹司琼盐酸盐的改进方法
CNA2006101667179A Pending CN101045704A (zh) 2001-01-11 2002-01-11 制备纯二水合昂丹司琼盐酸盐的改进方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006101667179A Pending CN101045704A (zh) 2001-01-11 2002-01-11 制备纯二水合昂丹司琼盐酸盐的改进方法

Country Status (21)

Country Link
EP (1) EP1355881A4 (is)
JP (1) JP2004526692A (is)
KR (3) KR20070054749A (is)
CN (2) CN1496350A (is)
AU (1) AU2002236753B2 (is)
CA (1) CA2433720A1 (is)
CZ (1) CZ20032090A3 (is)
DE (1) DE02703115T1 (is)
ES (1) ES2219201T1 (is)
HR (1) HRP20030631A2 (is)
HU (1) HUP0400767A2 (is)
IL (1) IL156835A0 (is)
IS (1) IS6869A (is)
MX (1) MXPA03006215A (is)
NO (1) NO20033147L (is)
PL (1) PL368837A1 (is)
SK (1) SK9892003A3 (is)
TR (1) TR200401460T3 (is)
WO (1) WO2002055492A2 (is)
YU (1) YU56103A (is)
ZA (1) ZA200305338B (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1499623E (pt) 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
WO2006046253A1 (en) * 2004-10-26 2006-05-04 Ipca Laboratories Limited A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
EP1339707A2 (en) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Also Published As

Publication number Publication date
HUP0400767A2 (hu) 2004-07-28
JP2004526692A (ja) 2004-09-02
ZA200305338B (en) 2004-07-12
EP1355881A4 (en) 2004-03-31
EP1355881A2 (en) 2003-10-29
AU2002236753B2 (en) 2007-06-28
SK9892003A3 (en) 2004-05-04
TR200401460T3 (is) 2004-08-23
KR20060113792A (ko) 2006-11-02
NO20033147D0 (no) 2003-07-09
HRP20030631A2 (en) 2005-06-30
NO20033147L (no) 2003-09-02
YU56103A (sh) 2006-05-25
ES2219201T1 (es) 2004-12-01
MXPA03006215A (es) 2005-02-17
DE02703115T1 (de) 2004-10-21
WO2002055492A2 (en) 2002-07-18
CA2433720A1 (en) 2002-07-18
IL156835A0 (en) 2004-02-08
PL368837A1 (en) 2005-04-04
WO2002055492A3 (en) 2003-02-13
KR20070054749A (ko) 2007-05-29
KR20030068583A (ko) 2003-08-21
CZ20032090A3 (cs) 2004-08-18
CN101045704A (zh) 2007-10-03
IS6869A (is) 2003-07-08

Similar Documents

Publication Publication Date Title
CN101039917A (zh) 制备替米沙坦的方法
CN1582278A (zh) 多晶型rimonabant,其制备方法及含有它的药物组合物
CN1198799C (zh) (s)－2－乙氧基－3－[4－(2－{4－甲磺酰氧基苯基}乙氧基)苯基]丙酸的晶形
CN1293673A (zh) 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶
CN1068582C (zh) 制备二酰氯的方法
CN1496350A (zh) 制备纯二水合昂丹司琼盐酸盐的改进方法
CN1283625C (zh) 纯化的lasofoxifene及通过重结晶纯化外消旋lasofoxifene的方法
CN1284951A (zh) 用于治疗cns病症的三嗪化合物
CN1856471A (zh) 3－苯基磺酰基－8－哌嗪－1－基－喹啉的多晶型物
CN88100986A (zh) 芳香基哌嗪基-亚烷基苯基-杂环化合物
CN85105193A (zh) 制备苯并噻吩止腹泻剂方法
CN101062897A (zh) 一种制备2，3－二氢－1h－茚－1－胺及其衍生物的改进方法
CN1518540A (zh) 4-[4-[4-(羟基二苯基甲基)-1-哌啶基]-1-羟基丁基]-α,α-二甲基苯乙酸和其盐酸盐的新型结晶形式
US20060089502A1 (en) Ziprasidone process
CN1603324A (zh) 左旋卤代斯库利啉盐及其制备方法和用途
HK1040078B (zh) 3-(2，4-二氯苄基)-2-甲基-n-(戊璜酰基)-3h-苯并咪唑-5-羧酰胺的晶形
CN1030077A (zh) 法莫丁啶多晶型物及其制备方法
CN1768057A (zh) 罗格列酮马来酸盐多晶型物的制备方法
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
CN1228330C (zh) 咪唑衍生物或它们的盐
CN1668586A (zh) 制备1,3,5－三氨基苯并将其水解为高纯度间苯三酚的方法
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
CN1882526A (zh) 制备伏格列波糖的方法
CN1091743A (zh) 吡咯衍生物，其制备方法及其在治疗上的应用
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication